A Secret Weapon For "3
All enrolled patients who acquired at the very least one dose of zosuquidar or placebo through induction were monitored for your incidence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions have been relevant to the duration of extended and significant myelosuppression as is anticipated with induct